During the past decade, MSD Osterreich GmbH conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "MSD Osterreich GmbH" are "Contraception" (1 trials) and "Metastatic Castration-Resistant Prostate Cancer" (1 trials). Many other conditions were trialed in "MSD Osterreich GmbH" in a lesser frequency.

Most popular intervention types in "MSD Osterreich GmbH" are "Drug" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abiraterone acetate 1000 mg" (1 trials), "Belzutifan 120mg" (1 trials), "Carboplatin" (1 trials), "Dexamethasone 8 mg" (1 trials) and "Docetaxel 75 mg/m^2" (1 trials). Other intervention names were less common.

The vast majority of trials in "MSD Osterreich GmbH" are 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "MSD Osterreich GmbH". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in MSD Osterreich GmbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in MSD Osterreich GmbH, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".